Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?

CMS launched the Medicare GLP-1 Bridge on July 1, 2026, opening a temporary pathway for eligible Part D enrollees to access weight-loss glucagon-like peptide-1 receptor agonists (GLP-1 RAs) medications for a flat $50 co-pay.¹ However, new modeling suggests the program’s real-world reach may fall well short of the tens of millions of Medicare beneficiaries living with obesity, raising questions about how big and how costly this bridge will actually be.²

The bridge launches in the aftermath of the indefinite shelving of the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) model, which had been slotted to go live in January 2027 after the 6-month Medicare GLP-1 Bridge’s original concluding date.^3,4 Applications are still being accepted for the BALANCE model through July 31, 2026, but states that fail to join by January 1, 2027, “will only be allowed to participate at CMS’ discretion.”⁴

CMS Administrator Mehmet Oz, MD, said in the agency’s announcement that cost has kept many Americans from these treatments, framing the Bridge as a stopgap measure until broader reform takes hold.⁵ At present, he added, 3 medications are available: orforglipron (Foundayo; Eli Lilly), semaglutide (Wegovy; Novo Nordisk), and tirzepatide (Zepbound KwikPen; Eli Lilly).

How Many Beneficiaries Actually Qualify?

An estimated 20 million Medicare beneficiaries could meet clinical criteria for weight-loss medications, according to Ilya Yuffa, MBA, executive vice president of Eli Lilly and president of Lilly USA and Global Customer Capabilities.⁶ KFF’s analysis tells a narrower story. The organization found that about 13.3 million Medicare beneficiaries, or 24% of all beneficiaries, had obesity or were overweight by body mass index in 2023.² Once KFF excluded beneficiaries with type 2 diabetes, moderate to severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis—conditions for which GLP-1s are covered through standard Part D benefits and therefore excluded from the Bridge—as well as those already filling GLP-1 prescriptions, the eligible pool for the Bridge itself narrowed to an estimated 3.8 million Part D enrollees.

CMS’s provider-facing guidance confirms the Bridge is designed specifically for beneficiaries who are not eligible for GLP-1 coverage through their existing Part D benefit and who lack those disqualifying diagnoses, meaning prescribers will need to document exclusion criteria carefully before submitting a prior authorization.⁷

What Could the Bridge Cost Medicare?

At 10% to 25% uptake among eligible beneficiaries, the Bridge would cost Medicare an estimated $1.3 billion to $3.3 billion over its 18-month run.² On the higher end of uptake, or 50% to 75% uptake, the price tag could climb to between $6.7 billion and $10 billion. These are figures that reflect the negotiated net price CMS says manufacturers agreed to supply eligible GLP-1s at—$245 per monthly supply minus the co-pay—which sits below the drugs’ list price but is paid outside the standard Part D benefit design, meaning none of it counts toward a beneficiary’s gross covered drug costs or true out-of-pocket spending.⁸

CMS tapped Humana to serve as the Bridge’s single central processor, managing prior authorization, claims adjudication, and pharmacy payment outside the normal Part D infrastructure.⁹ Part D plan sponsors do not need to opt in for their enrollees to access the Bridge, and pharmacies do not need to separately enroll to participate; CMS assigned a dedicated Bank Identification Number and Processor Control Number for claims routed to the central processor.^8,9 Because the Bridge operates as a primary payer without benefit coordination, coupons and manufacturer discount programs cannot be applied to Bridge claims, and only electronic claims will be accepted.⁹

What Does This Mean for Managed Care Stakeholders?

As explained above, the Bridge emerged after CMS’ original timeline stretched into an 18-month program, once the BALANCE’s Model rollout was delayed, leaving a longer but still temporary coverage window and no guaranteed transition path once the Bridge expires at the end of 2027.³ The gap between CMS’ broader eligibility framing¹ and KFF’s narrower estimate² may likely shape how plan sponsors and pharmacy benefit managers forecast utilization and budget impact through 2027.

With participation-dependent costs ranging from roughly $1.3 billion to $10 billion, and clinical documentation requirements still being worked out between prescribers and the central processor, the Bridge’s ultimate scale remains an open question for the managed care community to watch closely.

References

1. CMS launches Medicare GLP-1 Bridge, expanding access to GLP-1 medications. News release. CMS. July 1, 2026. Accessed July 6, 2026. https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications
2. Cubanski J, Sroczynski N. Nearly four million Medicare beneficiaries met the eligibility criteria in 2023 for the Medicare GLP-1 Bridge. KFF. June 29, 2026. Accessed July 6, 2026. https://www.kff.org/medicare/nearly-four-million-medicare-beneficiaries-met-the-eligibility-criteria-in-2023-for-the-medicare-glp-1-bridge/
3. Hohmann E. What you need to know before the Medicare GLP-1 Bridge goes live. AJMC^®. June 2, 2026. Accessed July 6, 2026. https://www.ajmc.com/view/what-you-need-to-know-before-the-medicare-glp-1-bridge-goes-live
4. CMS delays Part D portion of BALANCE Model on expansion of GLP-1 access. American Hospital Association. April 22, 2026. Accessed July 6, 2026. https://www.aha.org/news/headline/2026-04-22-cms-delays-part-d-portion-balance-model-expansion-glp-1-access’
5. GLP-1 Bridge coming soon video. CMSHHSgov YouTube page. Accessed July 6, 2026. https://www.youtube.com/watch?v=_xtjXIoxwYk&t=33s
6. Minemyer P. CMS goes live with GLP-1 Bridge program for Part D beneficiaries. Fierce Healthcare. July 1, 2026. Accessed July 6, 2026. https://www.fiercehealthcare.com/payers/cms-goes-live-glp-1-bridge-program-part-d-beneficiaries
7. Information for providers. CMS. Updated July 1, 2026. Accessed July 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
8. Information for Part D plans. CMS. Updated June 11, 2026. Accessed July 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
9. Information for pharmacies. CMS. Updated July 1, 2026. Accessed July 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies